Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

Clinical significance of DNA methylation in chronic lymphocytic leukemia patients: results from 3 UK clinical trials.

Wojdacz TK, Amarasinghe HE, Kadalayil L, Beattie A, Forster J, Blakemore SJ, Parker H, Bryant D, Larrayoz M, Clifford R, Robbe P, Davis ZA, Else M, Howard DR, Stamatopoulos B, Steele AJ, Rosenquist R, Collins A, Pettitt AR, Hillmen P, Plass C, Schuh A, Catovsky D, Oscier DG, Rose-Zerilli MJJ, Oakes CC, Strefford JC.

Blood Adv. 2019 Aug 27;3(16):2474-2481. doi: 10.1182/bloodadvances.2019000237.

2.

Correction: Whole-genome sequencing of chronic lymphocytic leukaemia reveals distinct differences in the mutational landscape between IgHVmut and IgHVunmut subgroups.

Burns A, Alsolami R, Becq J, Stamatopoulos B, Timbs A, Bruce D, Robbe P, Vavoulis D, Clifford R, Cabes M, Dreau H, Taylor J, Knight SJL, Mansson R, Bentley D, Beekman R, Martín-Subero JI, Campo E, Houlston RS, Ridout KE, Schuh A.

Leukemia. 2019 Sep;33(9):2342. doi: 10.1038/s41375-019-0515-8.

PMID:
31316144
3.

MicroRNA profiling and identification of let-7a as a target to prevent chemotherapy-induced primordial follicles apoptosis in mouse ovaries.

Alexandri C, Stamatopoulos B, Rothé F, Bareche Y, Devos M, Demeestere I.

Sci Rep. 2019 Jul 3;9(1):9636. doi: 10.1038/s41598-019-45642-w.

4.

Age-related changes in the BACH2 and PRDM1 genes in lymphocytes from healthy donors and chronic lymphocytic leukemia patients.

Chi VLD, Garaud S, De Silva P, Thibaud V, Stamatopoulos B, Berehad M, Gu-Trantien C, Krayem M, Duvillier H, Lodewyckx JN, Willard-Gallo K, Sibille C, Bron D.

BMC Cancer. 2019 Jan 17;19(1):81. doi: 10.1186/s12885-019-5276-2.

5.

The Light Chain IgLV3-21 Defines a New Poor Prognostic Subgroup in Chronic Lymphocytic Leukemia: Results of a Multicenter Study.

Stamatopoulos B, Smith T, Crompot E, Pieters K, Clifford R, Mraz M, Robbe P, Burns A, Timbs A, Bruce D, Hillmen P, Meuleman N, Mineur P, Firescu R, Maerevoet M, De Wilde V, Efira A, Philippé J, Verhasselt B, Offner F, Sims D, Heger A, Dreau H, Schuh A.

Clin Cancer Res. 2018 Oct 15;24(20):5048-5057. doi: 10.1158/1078-0432.CCR-18-0133. Epub 2018 Jun 26.

6.

Whole-genome sequencing of chronic lymphocytic leukaemia reveals distinct differences in the mutational landscape between IgHVmut and IgHVunmut subgroups.

Burns A, Alsolami R, Becq J, Stamatopoulos B, Timbs A, Bruce D, Robbe P, Vavoulis D, Clifford R, Cabes M, Dreau H, Taylor J, Knight SJL, Mansson R, Bentley D, Beekman R, Martín-Subero JI, Campo E, Houlston RS, Ridout KE, Schuh A.

Leukemia. 2018 Feb;32(2):573. doi: 10.1038/leu.2017.311. Epub 2017 Nov 21.

7.

Extracellular vesicles of bone marrow stromal cells rescue chronic lymphocytic leukemia B cells from apoptosis, enhance their migration and induce gene expression modifications.

Crompot E, Van Damme M, Pieters K, Vermeersch M, Perez-Morga D, Mineur P, Maerevoet M, Meuleman N, Bron D, Lagneaux L, Stamatopoulos B.

Haematologica. 2017 Sep;102(9):1594-1604. doi: 10.3324/haematol.2016.163337. Epub 2017 Jun 8.

8.

Whole-genome sequencing of chronic lymphocytic leukaemia reveals distinct differences in the mutational landscape between IgHVmut and IgHVunmut subgroups.

Burns A, Alsolami R, Becq J, Stamatopoulos B, Timbs A, Bruce D, Robbe P, Vavoulis D, Clifford R, Cabes M, Dreau H, Taylor J, Knight SJL, Mansson R, Bentley D, Beekman R, Martín-Subero JI, Campo E, Houlston RS, Ridout KE, Schuh A.

Leukemia. 2018 Feb;32(2):332-342. doi: 10.1038/leu.2017.177. Epub 2017 Jun 6. Erratum in: Leukemia. 2017 Nov 21;:. Leukemia. 2019 Sep;33(9):2342.

9.

Characterization of TET and IDH gene expression in chronic lymphocytic leukemia: comparison with normal B cells and prognostic significance.

Van Damme M, Crompot E, Meuleman N, Maerevoet M, Mineur P, Bron D, Lagneaux L, Stamatopoulos B.

Clin Epigenetics. 2016 Dec 7;8:132. eCollection 2016.

10.

Targeted deep sequencing reveals clinically relevant subclonal IgHV rearrangements in chronic lymphocytic leukemia.

Stamatopoulos B, Timbs A, Bruce D, Smith T, Clifford R, Robbe P, Burns A, Vavoulis DV, Lopez L, Antoniou P, Mason J, Dreau H, Schuh A.

Leukemia. 2017 Apr;31(4):837-845. doi: 10.1038/leu.2016.307. Epub 2016 Oct 31.

PMID:
27795555
11.

NCRI phase II study of CHOP in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndrome.

Eyre TA, Clifford R, Bloor A, Boyle L, Roberts C, Cabes M, Collins GP, Devereux S, Follows G, Fox CP, Gribben J, Hillmen P, Hatton CS, Littlewood TJ, McCarthy H, Murray J, Pettitt AR, Soilleux E, Stamatopoulos B, Love SB, Wotherspoon A, Schuh A.

Br J Haematol. 2016 Oct;175(1):43-54. doi: 10.1111/bjh.14177. Epub 2016 Jul 5.

PMID:
27378086
12.

Avoiding false positive antigen detection by flow cytometry on blood cell derived microparticles: the importance of an appropriate negative control.

Crompot E, Van Damme M, Duvillier H, Pieters K, Vermeesch M, Perez-Morga D, Meuleman N, Mineur P, Bron D, Lagneaux L, Stamatopoulos B.

PLoS One. 2015 May 15;10(5):e0127209. doi: 10.1371/journal.pone.0127209. eCollection 2015.

13.

Lipoprotein lipase SNPs rs13702 and rs301 correlate with clinical outcome in chronic lymphocytic leukemia patients.

Rombout A, Stamatopoulos B, Lagneaux L, Lust S, Offner F, Naessens E, Vanderstraeten H, Verhasselt B, Philippé J.

PLoS One. 2015 Mar 26;10(3):e0121526. doi: 10.1371/journal.pone.0121526. eCollection 2015. Erratum in: PLoS One. 2015;10(6):e0131029.

14.

Opposite Prognostic Significance of Cellular and Serum Circulating MicroRNA-150 in Patients with Chronic Lymphocytic Leukemia.

Stamatopoulos B, Van Damme M, Crompot E, Dessars B, Housni HE, Mineur P, Meuleman N, Bron D, Lagneaux L.

Mol Med. 2015 Jan 9;21:123-33. doi: 10.2119/molmed.2014.00214.

15.

Global histone deacetylase enzymatic activity is an independent prognostic marker associated with a shorter overall survival in chronic lymphocytic leukemia patients.

Van Damme M, Crompot E, Meuleman N, Mineur P, Dessars B, El Housni H, Bron D, Lagneaux L, Stamatopoulos B.

Epigenetics. 2014 Oct;9(10):1374-81. doi: 10.4161/15592294.2014.969628.

16.

Immune impairments in multiple myeloma bone marrow mesenchymal stromal cells.

André T, Najar M, Stamatopoulos B, Pieters K, Pradier O, Bron D, Meuleman N, Lagneaux L.

Cancer Immunol Immunother. 2015 Feb;64(2):213-24. doi: 10.1007/s00262-014-1623-y. Epub 2014 Oct 24.

PMID:
25341809
17.

In vivo production of mesenchymal stromal cells after injection of autologous platelet-rich plasma activated by recombinant human soluble tissue factor in the bone marrow of healthy volunteers.

Philippart P, Meuleman N, Stamatopoulos B, Najar M, Pieters K, De Bruyn C, Bron D, Lagneaux L.

Tissue Eng Part A. 2014 Jan;20(1-2):160-70. doi: 10.1089/ten.TEA.2013.0244. Epub 2013 Sep 24.

PMID:
23924315
18.

Evidences of early senescence in multiple myeloma bone marrow mesenchymal stromal cells.

André T, Meuleman N, Stamatopoulos B, De Bruyn C, Pieters K, Bron D, Lagneaux L.

PLoS One. 2013;8(3):e59756. doi: 10.1371/journal.pone.0059756. Epub 2013 Mar 21.

19.

HDAC isoenzyme expression is deregulated in chronic lymphocytic leukemia B-cells and has a complex prognostic significance.

Van Damme M, Crompot E, Meuleman N, Mineur P, Bron D, Lagneaux L, Stamatopoulos B.

Epigenetics. 2012 Dec 1;7(12):1403-12. doi: 10.4161/epi.22674. Epub 2012 Oct 29.

20.

AMD3100 disrupts the cross-talk between chronic lymphocytic leukemia cells and a mesenchymal stromal or nurse-like cell-based microenvironment: pre-clinical evidence for its association with chronic lymphocytic leukemia treatments.

Stamatopoulos B, Meuleman N, De Bruyn C, Pieters K, Mineur P, Le Roy C, Saint-Georges S, Varin-Blank N, Cymbalista F, Bron D, Lagneaux L.

Haematologica. 2012 Apr;97(4):608-15. doi: 10.3324/haematol.2011.052779. Epub 2011 Nov 4.

21.

The source of human mesenchymal stromal cells influences their TLR profile as well as their functional properties.

Raicevic G, Najar M, Stamatopoulos B, De Bruyn C, Meuleman N, Bron D, Toungouz M, Lagneaux L.

Cell Immunol. 2011;270(2):207-16. doi: 10.1016/j.cellimm.2011.05.010. Epub 2011 May 30.

PMID:
21700275
22.

A rapid, simple, and reproducible method for the isolation of mesenchymal stromal cells from Wharton's jelly without enzymatic treatment.

De Bruyn C, Najar M, Raicevic G, Meuleman N, Pieters K, Stamatopoulos B, Delforge A, Bron D, Lagneaux L.

Stem Cells Dev. 2011 Mar;20(3):547-57. doi: 10.1089/scd.2010.0260. Epub 2010 Nov 9.

PMID:
20923277
23.

A molecular score by quantitative PCR as a new prognostic tool at diagnosis for chronic lymphocytic leukemia patients.

Stamatopoulos B, Meuleman N, De Bruyn C, Pieters K, Anthoine G, Mineur P, Bron D, Lagneaux L.

PLoS One. 2010 Sep 16;5(9). pii: e12780. doi: 10.1371/journal.pone.0012780.

24.

Modulated expression of adhesion molecules and galectin-1: role during mesenchymal stromal cell immunoregulatory functions.

Najar M, Raicevic G, Id Boufker H, Stamatopoulos B, De Bruyn C, Meuleman N, Bron D, Toungouz M, Lagneaux L.

Exp Hematol. 2010 Oct;38(10):922-32. doi: 10.1016/j.exphem.2010.05.007. Epub 2010 Jun 1.

PMID:
20570633
25.

The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis, down-regulates the CXCR4 chemokine receptor and impairs migration of chronic lymphocytic leukemia cells.

Stamatopoulos B, Meuleman N, De Bruyn C, Delforge A, Bron D, Lagneaux L.

Haematologica. 2010 Jul;95(7):1136-43. doi: 10.3324/haematol.2009.013847. Epub 2010 Feb 9.

26.

Antileukemic activity of valproic acid in chronic lymphocytic leukemia B cells defined by microarray analysis.

Stamatopoulos B, Meuleman N, De Bruyn C, Mineur P, Martiat P, Bron D, Lagneaux L.

Leukemia. 2009 Dec;23(12):2281-9. doi: 10.1038/leu.2009.176. Epub 2009 Aug 27.

PMID:
19710697
27.

In vitro study of matrix metalloproteinase/tissue inhibitor of metalloproteinase production by mesenchymal stromal cells in response to inflammatory cytokines: the role of their migration in injured tissues.

Tondreau T, Meuleman N, Stamatopoulos B, De Bruyn C, Delforge A, Dejeneffe M, Martiat P, Bron D, Lagneaux L.

Cytotherapy. 2009;11(5):559-69. doi: 10.1080/14653240903051541.

PMID:
19551542
28.

Gene expression profiling reveals differences in microenvironment interaction between patients with chronic lymphocytic leukemia expressing high versus low ZAP70 mRNA.

Stamatopoulos B, Haibe-Kains B, Equeter C, Meuleman N, Sorée A, De Bruyn C, Hanosset D, Bron D, Martiat P, Lagneaux L.

Haematologica. 2009 Jun;94(6):790-9. doi: 10.3324/haematol.2008.002626. Epub 2009 Apr 18.

29.

microRNA-29c and microRNA-223 down-regulation has in vivo significance in chronic lymphocytic leukemia and improves disease risk stratification.

Stamatopoulos B, Meuleman N, Haibe-Kains B, Saussoy P, Van Den Neste E, Michaux L, Heimann P, Martiat P, Bron D, Lagneaux L.

Blood. 2009 May 21;113(21):5237-45. doi: 10.1182/blood-2008-11-189407. Epub 2009 Jan 14.

PMID:
19144983
30.

Doubling time of soluble CD23: a powerful prognostic factor for newly diagnosed and untreated stage A chronic lymphocytic leukemia patients.

Meuleman N, Stamatopoulos B, Dejeneffe M, El Housni H, Lagneaux L, Bron D.

Leukemia. 2008 Oct;22(10):1882-90. doi: 10.1038/leu.2008.190. Epub 2008 Jul 17.

PMID:
18633433
31.

Gene expression pattern of functional neuronal cells derived from human bone marrow mesenchymal stromal cells.

Tondreau T, Dejeneffe M, Meuleman N, Stamatopoulos B, Delforge A, Martiat P, Bron D, Lagneaux L.

BMC Genomics. 2008 Apr 11;9:166. doi: 10.1186/1471-2164-9-166.

32.

Quantification of ZAP70 mRNA in B cells by real-time PCR is a powerful prognostic factor in chronic lymphocytic leukemia.

Stamatopoulos B, Meuleman N, Haibe-Kains B, Duvillier H, Massy M, Martiat P, Bron D, Lagneaux L.

Clin Chem. 2007 Oct;53(10):1757-66. Epub 2007 Aug 16.

33.

Valproic acid induces apoptosis in chronic lymphocytic leukemia cells through activation of the death receptor pathway and potentiates TRAIL response.

Lagneaux L, Gillet N, Stamatopoulos B, Delforge A, Dejeneffe M, Massy M, Meuleman N, Kentos A, Martiat P, Willems L, Bron D.

Exp Hematol. 2007 Oct;35(10):1527-37. Epub 2007 Aug 13.

PMID:
17697742

Supplemental Content

Loading ...
Support Center